Keryx offers a precision‑medicine platform that combines high‑throughput genomics, multi‑omics biomarkers, and machine‑learning to generate individual risk scores for chronic diseases such as cardiovascular disease, diabetes, and neurodegeneration. The platform provides clinical decision support for preventive interventions and supplies pharmaceutical partners with validated molecular targets to accelerate drug discovery.
Funding
Funding not disclosed
Founders
Product
Problem
Chronic diseases often develop silently and are diagnosed only after significant progression, limiting the effectiveness of treatments and increasing long‑term healthcare costs. Current medical approaches focus on managing symptoms rather than identifying individuals at risk before disease onset.
Solution
Keryx builds a precision‑medicine platform that uses advanced genomics and biomarker profiling to detect molecular signatures associated with chronic disease risk. By integrating large‑scale genetic data, multi‑omics biomarkers, and predictive analytics, the platform can stratify patients according to their likelihood of developing conditions such as cardiovascular disease, diabetes, or neurodegeneration. Early‑intervention strategies are then designed to target the identified pathways, enabling preventive therapeutic development and informing clinical trial cohorts. The same data infrastructure supports pharmaceutical partners in discovering and validating targets linked to chronic disease mechanisms, accelerating drug development pipelines while aiming to reduce downstream treatment costs.
Target Audience
Primary customers are pharmaceutical and biotech companies seeking target validation for chronic disease programs, as well as healthcare providers and research institutions that require predictive risk assessments for patient populations.
Features
- High‑throughput sequencing and multi‑omics pipelines for comprehensive genetic and biomarker discovery
- Machine‑learning models that predict individual risk scores for a range of chronic diseases
- Integrated data platform that links molecular signatures to therapeutic targets for drug discovery
- Clinical decision support tools that recommend personalized preventive interventions based on risk profiles
- Secure, HIPAA‑compliant data management enabling collaboration with research institutions and pharma partners